Recent News

BCI achieved a flawless result with no findings or non-conformities, marking an exceptional accomplishment

Abu Dhabi, November 13, 2025: In a landmark medical achievement, Burjeel Cancer Institute’s (BCI) Breast Cancer Clinical Care Program has received the Gold Certification from the Joint Commission International (JCI). The JCI Gold Certification, considered a global benchmark in healthcare excellence, is granted only to institutions that demonstrate the highest international standards in clinical care delivery. The accreditation acknowledges BCI’s strong commitment to continuously improving the delivery of quality healthcare services.

As part of the evaluation process, JCI’s expert panel visited the institute for a comprehensive and rigorous assessment. It involved an in-depth review of compliance with 164 measurable standards covering all aspects of cancer care, including leadership and governance, care delivery, patient safety, information and medication management, staff training and competency, as well as patient and family education.

BCI distinguished itself by achieving a flawless result with no findings or non-conformities, marking an exceptional accomplishment that highlights the dedication and professionalism of its team in delivering world-class cancer care.

Commenting on the achievement, Prof. Humaid bin Harmal Al Shamsi, CEO of BCI, said, “Receiving the JCI Gold Certification for our Breast Cancer Program is an international endorsement of the quality of care we provide and our commitment to advancing healthcare excellence in our region. This recognition is not merely an institutional milestone; it is a renewed promise to our patients that we remain devoted to offering comprehensive, safe, and compassionate care that meets global standards. We take pride in leading innovation and excellence in cancer care.”

The certification provides a robust institutional framework to enhance patient experience, improve staff efficiency, and ensure consistent and safe healthcare delivery. It also supports patient-centered care strategies and reinforces the institute’s commitment to addressing the physical, psychological, and social needs of patients and their families.

Established in 1994 as an affiliate of the Joint Commission (USA), Joint Commission International (JCI) is a globally recognized leader in healthcare accreditation. Operating in more than 70 countries, JCI promotes quality improvement and patient safety through rigorous accreditation programs and internationally recognized standards. For more information, visit: www.jointcommissioninternational.org

The Group won awards in the ‘Establishments’ and ‘Outstanding Workforce’ categories, reaffirming its commitment to developing a dynamic and healthy workplace 

Abu Dhabi, November 14, 2025: Strengthening its reputation for workplace excellence, Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, has secured two awards at the third edition of the prestigious Emirates Labour Market Awards. Organized by the Ministry of Human Resources and Emiratisation (MOHRE), the ceremony was held under the patronage of His Highness Sheikh Mansour bin Zayed Al Nahyan, Vice President, Deputy Prime Minister, and Chairman of the Presidential Court. 

In the Establishments category, LLH Hospital, Abu Dhabi, received recognition in the Healthcare Company sub-category. For LLH Hospital, this marks a hat-trick win at the Labour Market Awards. In the inaugural edition, it was honored for its outstanding achievement in Workforce Well-being and the Quality of Life category, followed by the Establishments — Healthcare and Social Work category in the second edition.  

The Group also excelled in the Outstanding Workforce category, with Anas Kadiyarakam, Regional HR Manager at Burjeel Holdings, securing first place in the Management and Executives sub-category. He received a cash prize of one hundred thousand dirhams, an Apple Watch, a gold coin, and a Fazaa privilege card.  

The winners were honoured by His Highness Theyab bin Mohamed bin Zayed Al Nahyan, Deputy Chairman of the Presidential Court for Development and Fallen Heroes’ Affairs. 

Anas, a first-time recipient of this award, said that it’s a proud milestone in his career. He started his journey at Burjeel Holdings in 2009 as an HR Executive. From there, he was promoted to the roles of HR Officer, Assistant Manager, and then Manager. Currently, he serves as the Regional HR Manager, overseeing hospitals and international projects across the region. “I feel so honored to receive this prestigious award. I consider it a recognition from the UAE for being part of its labor force for the past 16 years. I’m also thankful to the Burjeel family for providing me with amazing opportunities that have catalyzed my career growth and enabled me to contribute to the overall development of the nation. This award also serves as a powerful reminder to continue creating a healthy workplace where people can thrive,” he said. 

Reflecting on the achievement, Dr. Tahani Al Qadiri, Group Director of Emiratization and Academics at Burjeel Holdings, said, “We feel immensely proud to receive this esteemed recognition once again, which honors the continuous efforts we put forward in building an inclusive, sustainable, and empowering workplace. At Burjeel Holdings, we remain focused on investing in our people, as we know they are the driving force behind exceptional care and innovation in healthcare. This honor inspires us to continue cultivating a healthy workforce and, in doing so, contribute to the UAE’s vision of cultivating world-class work environments.” 

The winners, comprising companies and individuals, were chosen from over 18,000 applications, reviewed by expert committees using comprehensive and integrated criteria. 

Over 700 specialists gather at the Fourth Emirates Pediatric BMT and Gene Therapy Congress to share breakthroughs, celebrate treatment success, and strengthen the UAE’s position as a hub for advanced pediatric care. 

Abu Dhabi, November 8, 2025: Reinforcing the UAE’s ambition to emerge as a global leader in advanced pediatric care and its growing reputation as a hub of medical excellence and innovation, Abu Dhabi hosted the Fourth Emirates Pediatric Bone Marrow Transplantation and Gene Therapy Congress, which opened today at the Grand Hyatt Abu Dhabi Hotel & Residences. The two-day congress brings together global leaders in pediatric hematology, oncology, and cellular therapy, underscoring the nation’s vision to position itself at the forefront of complex and life-saving medical treatments. 

This year’s congress, themed “An International Get-Together of Pediatric BMT Physicians to Celebrate the Success of Saving Children Globally,” reflects the spirit of collaboration and shared progress that defines the global pediatric bone marrow transplant community. The theme highlights the dedication of physicians, researchers, and healthcare institutions working together to advance curative treatments for children with rare and life-threatening blood disorders. 

A Two-Day Comprehensive Scientific Program 

The congress brings together more than 700 delegates and over 30 distinguished speakers from across 30 countries, including the United States, the United Kingdom, Spain, France, Italy, Saudi Arabia, India, and Jordan. Participating institutions include Burjeel Medical City (BMC), Children’s Hospital of Philadelphia, Cincinnati Children’s Hospital, Children’s Hospital Los Angeles, and SJD Barcelona Children’s Hospital. 

This year’s congress features a comprehensive scientific program encompassing keynote lectures, expert panels, oral and poster presentations, and industry symposia. Topics being discussed include the latest advances in gene therapy for thalassemia and sickle cell disease, haploidentical and matched sibling transplantation, CAR-T cell therapy, and transplant immunology. Sessions also explore donor stem-cell manipulation, supportive care, long-term survivorship, and regional access to cell and gene therapy innovations. 

The congress also focuses on the UAE’s growing contributions to regional healthcare advancement, including the development of national stem cell donor registries, collaboration with the Abu Dhabi Biobank to enhance cell therapy research, and strategies to increase access to gene therapy and transplantation across the Gulf region. 

Ahead of the main sessions, the Pediatric Bone Marrow Transplant Course 2025 offered intensive hands-on and theoretical training for young clinicians and researchers in pediatric transplantation. Led by international faculty, the course covered donor selection, stem cell harvesting and cryopreservation, conditioning regimens, and post-transplant management, equipping participants with practical skills to strengthen regional capacity. 

“This congress reflects how far we have come as a region in advancing pediatric transplantation and gene therapy. Supporting this significant event, our goal at BMC, is to provide children and families in the UAE and across the region with access to the best possible care, without the need to travel abroad. Along with the treatment center we are strengthening research, and collaboration that drives new standards in pediatric care,” said Dr. Zainul Aabideen, Congress Chair and Head of Pediatric Hematology, Oncology, and Bone Marrow Transplantation at Burjeel Cancer Institute, BMC. 

Dr. Aabideen presented to the delegates how BMC, which became home to the UAE’s first comprehensive pediatric bone marrow transplant program, has achieved survival rates of over 90 percent in the past three years. The milestone underscores Abu Dhabi’s emergence as a regional referral destination for complex pediatric cases and aligns with the UAE’s broader healthcare strategy to build self-sufficiency through advanced clinical capabilities and local talent development. 

Delegates reaffirmed their shared goal of advancing knowledge, expanding research collaboration, and accelerating access to gene therapy for children with rare and inherited disorders. With its focus on innovation, education, and global partnership, the congress celebrates the collective success of pediatric bone marrow transplant programs worldwide and underscores the UAE’s leadership in shaping the future of pediatric medicine. 

KSA Health Minister HE Fahad Abdulrahman AlJalajel, felicitated Dr. Shamsheer Vayalil, Founder and Chairman of the Group, for initiatives advancing healthcare transformation in line with Vision 2030.

Riyadh, October 28, 2025: Burjeel Holdings, a leading super-specialty healthcare services provider in MENA, unveiled a suite of advanced artificial intelligence (AI) solutions at the Global Health Exhibition 2025 in Riyadh, underscoring its commitment to transforming patient care and advancing Saudi Arabia’s healthcare ecosystem.

During the opening ceremony, HE Fahad Abdulrahman AlJalajel, Minister of Health, felicitated Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, for the Group’s initiatives that advance healthcare transformation in line with Saudi Arabia’s Vision 2030.

Integrating Care and Intelligence

Under the theme ‘Care & Intelligence – World-Class Healthcare for the Kingdom,’ Burjeel Holdings is showcasing how technology, data, and empathy converge to redefine healthcare experiences. The Group is demonstrating a new generation of AI-driven innovations designed to elevate patient outcomes, streamline clinical workflows, and support wellness through personalized, data-informed care models.

“The Global Health Exhibition provides an important platform to demonstrate how care and intelligence can come together to reshape the healthcare experience. With these integrated AI-driven healthcare innovations, we are building a smarter, more compassionate healthcare future that meets the evolving needs of our patients and communities. Our goal is to seamlessly blend cutting-edge technology with human-centered care to elevate health outcomes and quality of life across the region,” said Mr. Safeer Ahamed, Co-CEO of Burjeel Holdings.

The newly introduced AI solutions span a wide spectrum of applications, from digital rehabilitation platforms that enable patients to undergo guided physiotherapy from home to intelligent surgical systems that connect specialists virtually to perform and supervise procedures in real time. These innovations combine clinical expertise with automation and analytics to ensure accuracy, safety, and accessibility in every phase of care.

Another key innovation focuses on predictive and personalized health management. Through data modeling and biomarker analysis, the Group’s new digital health platforms can identify early risks, optimize preventive care, and generate tailored lifestyle and nutrition insights. This approach allows clinicians to transition from reactive to proactive care models, improving health outcomes and patient satisfaction.

Advancing Personalized, Preventive, and Mental Health Solutions

In musculoskeletal and rehabilitation care, Burjeel Holdings continues to deploy personalized and digital therapeutics that deliver home-based physiotherapy and pain management programs. These solutions use real-time monitoring to ensure continuous recovery support and data-driven therapy optimization.

In specialty and complex care, the Group continues to advance precision medicine through diagnostic and therapeutic programs that leverage molecular and clinical data. Collaborations

with international partners and ongoing clinical trials are helping bring personalized treatments and innovative therapies to patients across the region.

To promote holistic health and longevity, Burjeel Holdings is introducing digital platforms that combine genetic, biomarker, and lifestyle data to provide actionable insights and personalized recommendations for nutrition, fitness, and preventive care. Complementing these initiatives, the Group is integrating empathetic AI-powered companions that support mental and emotional well-being through guided assistance and culturally attuned digital engagement.

Across its facilities, the Group is also integrating generative AI tools that improve clinical workflows and communication between patients and care teams. These intelligent systems enhance efficiency, safety, and patient experience, reflecting the Group’s vision to make healthcare more connected, compassionate, and data-driven.

Since entering the Kingdom three years ago, Burjeel Holdings has evolved from a regional healthcare leader to a trusted local partner. Its brands, including PhysioTherabia and Al Kalma, have established a strong presence across wellness and mental health services. Al Kalma’s recent acquisition of a leading mental health facility in Riyadh further underscores the Group’s dedication to expanding access to emotional and psychological support. Burjeel Holdings is also preparing to open two new day surgery centers in Riyadh and Al Khobar under its Burjeel One brand, offering world-class outpatient and same-day surgical care.

These innovations reflect Burjeel Holdings’ vision of building a more connected, efficient, and patient-centric healthcare ecosystem across the Kingdom. The solutions are being integrated within the Group’s expanding network across the region to improve access, enhance clinical training, and reduce the burden of chronic and lifestyle-related diseases. These developments reinforce the Group’s role as a key contributor to Saudi Arabia’s efforts to localize advanced healthcare capabilities and expand digital health infrastructure.

An advanced, non-invasive test, Trucheck is capable of identifying over 70 solid tumors 

Dubai: In an effort to support preventive cancer care, Burjeel Hospitals, has announced the launch of Trucheck™ intelli, an advanced, non-invasive testing method for the early detection of cancer. A breakthrough in integrative diagnostic technology and personalized care, Trucheck requires just a simple blood test and is capable of identifying more than 70 solid tumors.  

A Simple Method Offering Precise, Personalized Care 

Globally, the cancer burden continues to grow, putting tremendous physical, financial, and emotional strains on individuals and families. According to the World Health Organization (WHO), cancer is the second leading cause of death globally. However, the survival rate can be improved through early detection and advanced care. Trucheck plays a vital role in achieving this.   

By introducing Trucheck at Burjeel Hospitals, Burjeel Cancer Institute (BCI) is taking the lead in preventive cancer care. This cutting-edge test is designed to detect circulating tumor cells (CTCs) and molecular signatures indicative of cancer. With its advanced diagnostic capabilities, Trucheck enables early cancer detection, often before symptoms arise, setting a new standard in non-invasive, preventive healthcare.  

“Trucheck has shown an exceptional accuracy rate exceeding 95% in detecting more than 70 types of cancers such as breast, lung, pancreatic, liver, thyroid, and gastrointestinal cancers. Unlike tests that depend mainly on circulating tumor DNA (ctDNA) methylation patterns, Trucheck emphasizes intact tumor cells as its biomarker. The rationale is that CTCs might give a more direct signal of malignancy and provide more morphological and protein-level information,” explained Prof. Humaid Al Shamsi, CEO, Burjeel Cancer Institute (BCI), who has contributed to the research behind Trucheck. With rapid result turnaround, the test helps clinicians make timely and personalized treatment decisions.  

Preventive Screening for Adults Aged 40 and Above 

Unlike traditional testing methods, Trucheck doesn’t require fasting or preparation. Asymptomatic individuals aged 40 and above can benefit from this method, which serves as a valuable preventive tool for the general population, high-risk individuals with genetic or family histories, and patients under post-treatment surveillance. It provides highly accurate, research-backed results with minimal false positives or negatives. One can opt for this test once a year to ensure a cancer-free life. 

“In cancer care, early diagnosis is the cornerstone. It makes a huge difference. By introducing Trucheck, we are bringing unprecedented precision and accessibility to preventive cancer care. Giving access to early diagnosis can save lives while reducing the social and economic burden of cancer,” added Dr. Humaid. 

Catching cancer early can make the journey more manageable. It opens the door to more treatment options, better outcomes, and a greater chance of recovery. With its ability to detect cancer at its earliest stages, Trucheck has the potential to transform the way cancer is diagnosed, treated, and managed.  

Burjeel Medical City was honored in the ‘Large Facility’ category, and six Emirati employees of the Group received individual awards for their excellence in medical, administrative, healthcare, and leadership roles 

Abu Dhabi: Burjeel Holdings, a leading super-specialty healthcare services provider in MENA, has once again excelled at the Nafis Award, a recognition of its commitment to empowering Emirati professionals and building sustainable career pathways in healthcare. This year, the Group received seven awards in ‘Large Facility’ and ‘Individual’ categories for its ongoing efforts to attract, develop, and retain UAE Nationals across its facilities.  

The Nafis Award, an initiative launched as part of the ‘Projects of the 50’ agenda, aims to enhance the competitiveness of Emirati human resources and empower them to occupy jobs in the private sector. The award was launched under the patronage and guidance of His Highness Sheikh Mansour bin Zayed Al Nahyan, Vice President, Deputy Prime Minister, Minister of the Presidential Court, Chairman of the Emirati Talent Competitiveness Council. The winners were announced during the third cycle of the award ceremony held in Abu Dhabi.  

While Burjeel Medical City (BMC) won first place in the ‘Large Facility’ category, six Emirati employees received individual awards for their excellence in medical, administrative, healthcare, and leadership roles. Dr. Naser Alriyami, CEO of Al Dhafra Region, Burjeel Holdings, and Dr. Mohamed Almarzooqi, Medical Director & Consultant Interventional Radiology, Burjeel Hospital, Abu Dhabi, won first and second place in the ‘Leadership’ category, respectively. In the ‘Healthcare’ category, Sara Alkatheeri and Fatma Ben Ammar, Nutritionists at BMC, won first and third place, respectively. Dr. Mohamed Muath ADI, Head of Department & Consultant Orthopedic Surgeon, BMC, received second place in the ‘Medical’ category, while Alya Almazrouei, Manager, Outreach and Stakeholder Engagement, Burjeel Holdings, won second place in the ‘Administrative’ category.  

“We are honored to receive these awards that recognize our ongoing efforts to invest in Emirati talent and strengthen their contributions to the private healthcare sector. We are proud to see them leading transformation across our facilities, contributing meaningfully at every level. Their growth reflects our deep-rooted commitment to building a future-ready healthcare workforce shaped by local talent,” said Dr. Shamsheer Vayalil, Founder and Chairman, about the achievement.  

Over the years, Burjeel Holdings has steadily increased the number of UAE Nationals across its facilities, investing in structured training, mentorship, and development programs. 

 Dr. Tahani Al Qadri, Group Director of Emiratization and Academics at Burjeel Holdings, said, “Our Emirati colleagues play an essential role in shaping the future of healthcare in the UAE. At Burjeel Holdings, we are actively building pathways for Emirati talent to thrive across a range of roles, including leadership. Through targeted programs, mentorship, and strategic partnerships like Nafis, we’re integrating local talent into every layer of our healthcare ecosystem and equipping them with the skills and experiences needed for long-term success.” 

Over the past two years, Burjeel Holdings saw a 300% increase in the number of UAE Nationals across its units, with nearly 30% now serving in senior roles. Its initiatives continue to inspire more young Emiratis to pursue meaningful careers in healthcare.  

Breast cancer treatment is often a journey filled with complex decisions. A 51-year-old woman, previously treated for breast cancer, presented with a new challenge—an ulcerative lesion in the nipple-areola complex (NAC). Initially misdiagnosed as triple-negative breast cancer, further evaluation at Burjeel Breast Center revealed Paget’s disease with ductal carcinoma in situ (DCIS). 

Accurate Diagnosis 

Expert review by Burjeel’s pathology team prevented unnecessary chemotherapy. This highlights the importance of second opinions and precise pathology in cancer care. 

Surgical Management 

The patient required excision of the entire NAC and surrounding ulcerated skin (8 × 6 cm). Wishing to preserve her implant-based reconstruction, she declined invasive options such as latissimus dorsi flap. The surgical team recommended a Medial Intercostal Artery Perforator (MICAP) flap with skin paddle, a muscle-sparing technique ideal for such complex cases. 

The Procedure 

Surgeons successfully performed a wide local excision followed by immediate partial breast reconstruction. The MICAP flap allowed skin resurfacing while preserving the implant. The patient recovered smoothly, with excellent cosmetic and functional results. 

Outcome and Follow-up 

Final histology confirmed Paget’s disease with DCIS—completely excised with clear margins and no invasive carcinoma. Multidisciplinary review concluded the surgery was curative, eliminating the need for further treatment. 

Conclusion 

This case underscores Burjeel Cancer Institute’s expertise in delivering personalized, minimally invasive breast reconstruction solutions, helping women regain both health and confidence after cancer surgery. 

Our Experts

Dr. Hazem Khout

Consultant Breast Oncoplastic Surgeon, Burjeel Cancer Institute 

View Profile

Dr. Omar Layth Qassid

Consultant Anatomic Pathology, Burjeel Medical City

View Profile

Dr. Lakshmanarajan Karuppasamy Mariyamma

Specialist Anesthesia, Burjeel Medical City 

View Profile

Breakthrough findings offer hope to over 500 million people living with diabetes and new solutions in remote healthcare.

NEW YORK, September 26, 2025 – Axiom Space and Burjeel Holdings released the preliminary results of the “Suite Ride” research conducted during the Axiom Mission 4 (Ax-4). The research concluded that everyday diabetes tools used by millions on Earth can be used comprehensively to provide end-to-end diabetes monitoring from space to ground and back to space—a breakthrough in opening the door to future astronauts with diabetes and providing new solutions in remote healthcare.

The results were revealed at a ceremony held at Burjeel Institute for Global Health, New York, in the presence of global space and healthcare experts, and teams from Axiom Space and Burjeel Holdings. Building on these findings, the healthcare group also announced its ambition of working toward sending the first astronaut with diabetes into space.

Axiom Space and Burjeel Holdings teamed up on the research program during the Ax-4 mission aboard the International Space Station this summer. Sending up a suite of remote care capabilities, the Suite Ride initiative explored how to manage diabetes in space, marking a meaningful step toward making spaceflight accessible for those with historically disqualifying conditions.

The research results found that continuous glucose monitors (CGMs) and insulin pens can operate reliably in the extreme conditions of space. Early results suggest that CGM devices can perform with accuracy comparable to Earth-based readings, enabling real-time glucose monitoring of astronauts in microgravity and can communicate readings to the ground. Insulin pens flown on the space station are now undergoing post-flight testing to evaluate the integrity of the formulation. This continues research from Virgin Galactic’s Galactic 07 mission where a successful technical demonstration was conducted confirming that commercially available insulin pens can dispense accurate doses in microgravity, aligning with International Organization for Standardization (ISO) guidelines.

“This is about inspiring people everywhere,” said Gavin D’Elia, Global Head of Pharma, Axiom Space. “A diagnosis shouldn't end your dream of space exploration. Together, we’re advancing the potential to fly the first astronaut with diabetes and to unlock innovation in healthcare.”

The Suite Ride initiative delivered several historic firsts:

• First continuous glucose monitoring of crew aboard the space station
• First insulin pens ever flown to station
• First validation of glucose monitoring across multiple measurement methods on the space station

Beyond the benefits to space exploration, the research findings extend to advancing remote and underserved communities worldwide. “Burjeel Holdings initiated this study to pioneer space medicine in line with the UAE’s space ambitions. Besides opening the door for astronauts with diabetes, these findings will also transform the way we deliver care here on Earth. From 250 miles above Earth to 25 miles offshore on oil rigs, we are advancing new models of remote care,” said Dr. Mohammad Fityan, Chief Medical Officer at Burjeel Medical City and Clinical Lead of the Burjeel–Ax-4 Space Health Research.

The research builds on a long tradition of space-driven medical innovation. In the 1970s, a miniaturized pump designed for the Viking Mars lander was adapted into the world’s first wearable insulin pump and used by millions of patients. The Suite Ride initiative represents the next chapter in this legacy, opening space to populations previously excluded and advancing real-time medical monitoring for extreme environments on Earth and beyond.

Axiom Space and Burjeel Holdings will continue to work together to find innovative solutions in chronic disease management for use on and off the planet.

ABOUT AXIOM SPACE Axiom Space is building the world’s first commercial space station – Axiom Station. Serving as a cornerstone for sustained human presence in space, this next-generation orbital platform fosters groundbreaking innovation and research in microgravity, and cultivates the vibrant, global space economy of tomorrow. Today, driven by the vision of leading humanity's journey off planet, Axiom Space is the principal provider of commercial human spaceflight services to the International Space Station and developer of advanced spacesuits for the Moon and low-Earth orbit. Axiom Space is building era-defining space infrastructure that will empower our civilization to transcend Earth for the benefit of every human, everywhere. For more information about Axiom Space, visit www.axiomspace.com.

ABOUT BURJEEL HOLDINGS

Founded in 2007, Burjeel Holdings is a leading super-specialty healthcare services provider in the UAE and Oman, and it operates a growing specialized healthcare segment in Saudi Arabia. The Group operates an integrated and multi-brand healthcare ecosystem across primary, secondary, tertiary, and quaternary medical care, ensuring complex care delivery to patients across all socioeconomic groups. Its network comprises 112 assets across the UAE, Oman, and Saudi Arabia, including 20 hospitals, 37 medical centers, 30 physiotherapy and wellness centers, 15 pharmacies, and 10 other allied services. Burjeel Holdings’ brands include Burjeel, Medeor, LLH, Lifecare, PhysioTherabia and Tajmeel.

Media Contacts: media@axiomspace.com

krish@burjeelholdings.com

The Burjeel by the Beach Clinic was inaugurated by H.E. Sheikh Zayed bin Saeed bin Zayed Al Nahyan and H.E. Sheikh Hamdan bin Saeed bin Zayed Al Nahyan  

Abu Dhabi, May 28: Burjeel Holdings, a leading provider of super-specialty healthcare services in the MENA region, has officially inaugurated the Burjeel by the Beach Clinic at Abu Dhabi’s Saadiyat Island, marking a significant step in its ongoing commitment to expanding access to premium healthcare across the UAE. Strategically located in the heart of Saadiyat Island, the center is designed to serve the diverse community of residents, expatriates, tourists, and corporate professionals. The new center was launched by H.E. Sheikh Zayed bin Saeed bin Zayed Al Nahyan and H.E. Sheikh Hamdan bin Saeed bin Zayed Al Nahyan. 

The launch event was attended by Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, Mr. Saif Alfalahi, Vice Chairman & Non-Executive Director – Independent, Burjeel Holdings, and Mr. Omran Al Khoori, Executive Director, Burjeel Holdings, along with members of Burjeel’s senior management.  

The center’s design embraces a ‘Burjeel by the Beach’ theme, creating a serene, coastal-inspired atmosphere that mirrors the tranquil surroundings of Saadiyat Island. This patient-centered approach ensures that the medical center provides expert care and a calming environment where individuals and families can prioritize their health and well-being. 

The facility offers a comprehensive range of services, including Family Medicine, Internal Medicine, Pediatrics, Obstetrics & Gynecology, and Psychiatry. In addition to its consulting doctors, the center will welcome visiting specialists from Burjeel’s broader network, ensuring continuous access to diverse medical expertise. For patients requiring more specialized interventions, the center will facilitate referrals to the Group’s flagship facility, Burjeel Medical City, for advanced care. 

The center has state-of-the-art diagnostic technologies, including X-ray and ultrasound imaging, providing patients with fast, accurate diagnostic assessments. A fully integrated in-house pharmacy further enhances the center’s ability to deliver seamless care, enabling patients to access diagnostics, consultations, and medications all in one convenient location. 

The center features six fully equipped consultation rooms, five specialized departments, and a dedicated treatment room. In addition, services such as phlebotomy for lab testing and on-site imaging ensure that patients receive a convenient and efficient care experience from start to finish. 

“The opening of Burjeel by the Beach Clinic at Saadiyat Island is a key milestone in our mission to bring world-class healthcare closer to our communities. We are proud to offer a facility that combines expert care with a welcoming environment, allowing individuals and families to focus on their health and well-being,” said Mr. John Sunil, Group CEO of Burjeel Holdings. 

The center will engage the community through wellness programs and corporate health partnerships, further nurturing preventive health practices and promoting the overall well-being of individuals, families, and businesses on the island. 

“We are dedicated to providing holistic healthcare that meets the diverse needs of our community. We focus on ensuring that every patient receives compassionate care that supports their physical and mental well-being in an environment that promotes healing and relaxation,” said Dr. Sonia Malik, Consultant, Family Medicine and Medical Director of Burjeel by the Beach Clinic, Saadiyat Island. 

The launch of Burjeel by the Beach Clinic at Saadiyat Island is part of Burjeel Holdings’ long-term healthcare expansion strategy, aimed at enhancing access to high-quality primary care while addressing the broad spectrum of healthcare needs in the community. 

Renowned orthopedic surgeon Prof. Dr. Munjed Al Muderis will offer cutting-edge osseointegration surgeries at the clinic 

Abu Dhabi | May 27, 2025: Ushering in a new era of prosthetic care in the UAE and across the region, Burjeel Medical City has launched the Al Muderis Osseointegration Clinic. The clinic is named after globally renowned orthopedic surgeon Prof. Dr. Munjed Al Muderis. As part of the Paley Middle East Clinic, the new center introduces to the region a groundbreaking surgical technique known as osseointegration, which anchors external prosthetic limbs directly to the bone, offering amputees enhanced mobility, stability, and comfort. 

The launch event was attended by Prof. Dr. Al Muderis, Dr. Dror Paley, founder of the Paley Middle East Clinic, and senior leadership from Burjeel Holdings, marking a significant milestone in making advanced amputee care more accessible to patients in the Middle East. 

At the heart of the clinic’s offering is the Osseointegrated Prosthetic Limb (OPL) system, which uses a titanium implant that integrates with the bone and extends through the skin to attach securely to an external prosthesis. This direct skeletal connection mimics natural limb movement and eliminates many limitations of conventional socket-based prosthetics. 

Unlike traditional prosthetic limbs, which can cause discomfort, skin issues, and joint complications, osseointegration enables a more intuitive, stable, and lifelike experience. The OPL not only improves balance and comfort but also allows for osseoperception, a phenomenon where users regain sensory feedback through the prosthetic. 

“Our goal has always been to restore mobility and dignity to amputees. By bringing this technology to the UAE, we’re building local capabilities and offering hope to those who have waited too long for the right kind of care,” said Prof. Dr. Al Muderis, who has treated more than 1,200 patients globally using this technology.  

The opening of the clinic marks a critical moment in the region’s healthcare evolution. The Middle East region is observed to have a comparatively higher prevalence of amputations, with a significant proportion resulting from trauma, particularly conflict-related and road-traffic injuries, which tend to impact younger age groups more. 

“The launch of the Al Muderis Osseointegration Clinic reinforces our commitment to bringing the world’s most advanced medical solutions to our communities. We envision this clinic not only as a center of excellence for patient care but also as a hub for knowledge transfer. Through surgeon training, research initiatives, and community outreach, we will extend this innovation across the UAE and beyond,” said Mr. John Sunil, Group CEO of Burjeel Holdings. 

Prof. Dr. Al Muderis, whose journey from fleeing Iraq as a refugee to becoming a globally respected surgeon has inspired many, emphasized the deeply personal mission behind the clinic. 

“Mobility is life,” he says. “Our mission is to ensure that limb loss never defines or limits a person’s future. Over the past decade, we pioneered the single-stage technique and enabled the technology for diabetic, vascular, pediatric, transtibial, and hip-disarticulation amputees. With this technology, we empower people with even the most complex injuries to reclaim their independence and quality of life.” 

Through expert second opinions, remote consultations, and visiting programs from leading global institutes, Burjeel Cancer Institute is set to transform the oncology landscape in the UAE 

Abu Dhabi, April 16, 2025: In a major step toward expanding access to world-class oncology services, Burjeel Cancer Institute (BCI), one of the largest cancer care networks in the UAE, has announced strategic collaborations with three globally renowned institutions — the European Institute of Oncology (IEO), the Children’s Hospital of Philadelphia (CHOP), and SJD Barcelona Children’s Hospital — during Abu Dhabi Global Healthcare Week. These partnerships aim to redefine oncology care in the region by advancing clinical services, research, education, and personalized oncology. 

BCI caters to over 5,000 patients each year and provides 360-degree tailored care, from diagnosis to survivorship programs. Its network is spread across the entire UAE, including key locations in Abu Dhabi, Al Ain, Dubai, Sharjah, and Al Dhafra, ensuring access to comprehensive and compassionate cancer care across all ages. 

These new collaborations will leverage teleconsultation and remote patient monitoring technologies, facilitate second opinions from international experts, and establish visiting programs to enable deeper knowledge exchange and enhance local capabilities. 

Enhancing Pediatric Cancer Care 

The Children’s Hospital of Philadelphia (CHOP) collaboration will enhance pediatric cancer care and strengthen capabilities in advanced diagnostics, remote consultations, and multidisciplinary second opinions. Visiting programs from CHOP will support knowledge exchange in subspecialized pediatric oncology. 

Mrs. Madeline Bell – President & Chief Executive Officer (CEO) for Children’s Hospital of Philadelphia (CHOP), said “We are excited to collaborate with BCI in advancing pediatric cancer care through shared expertise, remote care innovations, and training opportunities. Together, we will empower healthcare teams and support families facing childhood cancer.” 

The partnership with SJD Barcelona Children’s Hospital is set to further augment BCI’s capabilities in comprehensive childhood cancer care. The collaboration will offer continuous remote support and medical guidance, particularly for rare and complex pediatric cases. 

Dr. Manel del Castillo Rey – Chief Executive Officer (CEO) SJD Barcelona Children’s Hospital, commented, “Our collaboration with BCI provides a framework for sharing specialized knowledge and co-managing complex pediatric oncology cases. By bridging geographies, we can provide more children with access to expert care.” 

Integrating Global Expertise 

In partnership with the European Institute of Oncology (IEO), BCI will focus on strengthening cancer care in the UAE through clinical and scientific research development, training and education programs for healthcare professionals, and high-level clinical services. The collaboration will also support the creation of a distinguished network of visiting professors, capacity-building initiatives for nurses and pharmacists, and the establishment of a strategic advisory board for BCI. 

Ing. Mauro Melis – Chief Executive Officer IEO & Centro Cardiologico Monzino, said, “Our partnership with Burjeel Cancer Institute reflects a shared commitment to elevating standards in cancer care. Through collaborative research, clinical exchanges, and capacity-building, we aim to jointly accelerate innovation and improve outcomes for patients in the country and across the region.” 

Advancing Diagnostic Testing for Cancer 

In addition to these collaborations, Burjeel Cancer Institute also joined hands with AbbVie Biopharmaceuticals to advance a personalized medicine approach in cancer care. The collaboration aims to support the adoption and access to the latest testing techniques to enhance the diagnosis and treatment of patients with various types of cancer, including ovarian, lung, and colorectal malignancies. 

As part of this initiative, the anatomical pathology laboratory lead by Dr. Rawia Mubarak will introduce a test for the first time in the region for platinum-resistant ovarian cancer, which will help identify patients who may benefit from emerging targeted therapies—offering a more personalized path forward and renewed hope for better outcomes. 

Mr. Mohammad Aboubakr Abdulgawad Mohammad – General Manager for AbbVie Pharmaceuticals, said,“Through our collaboration with Burjeel Cancer Institute, we are proud to introduce this advanced test in the UAE, a critical step toward identifying individuals who may benefit from emerging targeted therapies. By adopting this innovation, physicians can offer a more personalized and effective approach to care.” 

Prof. Humaid Al Shamsi, CEO of Burjeel Cancer Institute, remarked, “These global partnerships are a pivotal step in our mission to bring world-class cancer care to the region. By aligning with some of the most prestigious institutions worldwide, we are building a future-ready oncology ecosystem that prioritizes quality, access, and innovation for every patient we serve.” 

These partnerships underscore BCI’s strategic vision to not only expand its clinical capabilities but also serve as a regional hub for knowledge, innovation, and excellence in oncology. 

The strategic collaboration brings next-gen AI pathology tools to the region, enhancing diagnostic accuracy and access to advanced cancer care 

Abu Dhabi | New York, April 16, 2025: Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, has announced a strategic partnership with Paige, a US-based leader in next-generation AI technology. The collaboration aims to enhance access to advanced cancer diagnostics by deploying Paige’s AI-powered solutions across Burjeel’s healthcare network. It also seeks to address the global shortage of pathologists and accelerate access to rapid, reliable cancer diagnostics, particularly in underserved communities and emerging markets. The collaboration was announced during Abu Dhabi Global Health week in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings.  

Paige has developed a suite of AI applications that support diagnostic decision making in cancer pathology. Paige Prostate Detect*, a key component of the suite, is the first FDA-approved AI algorithm, that works by detecting prostate cancer in core-needle biopsies. With this partnership, Burjeel Holdings will become one of the first in the region to offer these AI-powered diagnostic tools, reinforcing its commitment to delivering timely and accessible cancer care. Paige’s solutions are designed to augment the capabilities of pathologists, streamline workflows, and boost diagnostic confidence, ultimately resulting in better outcomes for patients. The partnership represents a significant step toward the democratization of advanced care, ensuring that even the most advanced technologies reach patients who need them most. 

“Our collaboration with Paige represents a transformative step in delivering cancer diagnostics across our network. By incorporating next-gen AI into our pathology services, we aim to enhance the speed and accuracy of cancer diagnosis, enabling more effective treatment decisions. This partnership also reflects our mission to bring world-class, technology-enabled care to emerging markets,” said John Sunil, Group CEO of Burjeel Holdings. 

Paige has earned multiple regulatory achievements in AI for pathology, including FDA Breakthrough Device Designation for Paige PanCancer Detect, Paige Breast Lymph Node, and Paige Prostate Detect. Burjeel Holdings will deploy these AI applications along with Paige OmniScreen, which simultaneously screens over 1,600 molecular biomarkers to support comprehensive cancer diagnosis and more personalized treatment. 

“Burjeel Holdings’ commitment to innovation and equitable care across the MENA region makes them a powerful ally in helping us close diagnostic gaps and bring the benefits of our AI technology to more patients, faster. This partnership helps deliver on our mission to make next-generation cancer diagnostics accessible worldwide and aligns with our vision to standardize access to cutting-edge diagnostics on a global scale,” said Peter Hamilton, General Manager of Diagnostics, Paige. 

The partnership marks a key milestone in positioning Burjeel Holdings as a regional hub for AI-enabled pathology, with the potential to scale this transformative technology across MENA and beyond.